Podcast Summary: The Ethics of Human Enhancement
Podcast: LSE: Public Lectures and Events
Episode: The Ethics of Human Enhancement
Date: October 30, 2012
Host: LSE Film and Audio Team
Speakers: Nick Bostrom (Philosophy, Oxford University) & Ann Kerr (Sociology, University of Leeds)
Main Theme: Exploring ethical, social, and philosophical questions raised by emerging technologies aimed at enhancing human capacities beyond normal health.
Episode Overview
This episode explores the ethical landscape of human enhancement, examining both the promise and the perils that come with technologies capable of improving human capacity—be it cognitive, physical, or emotional. Enhancements, as defined here, go beyond traditional therapies, raising complex questions about fairness, social inequality, unintended consequences, and the very definition of what it means to be human. Drawing on expertise in moral philosophy and sociology, Professors Nick Bostrom and Ann Kerr engage in a lively debate, discussing not only the theoretical implications but also the practical and societal ramifications of emerging biomedical and technological enhancements.
Key Discussion Points & Insights
1. Defining Human Enhancement and Its Distinctions
[00:20]
- Moderator notes that "enhancement" seeks to improve an organism beyond its normal healthy state, unlike therapy which aims to restore normalcy.
- Technologies under discussion: brain-computer interfaces, genetic engineering, smart drugs (e.g., for memory/concentration), brain implants.
Nick Bostrom: Introduces the need to distinguish between enhancement as a "positional good" (benefits you only relative to others) and as an "absolute good" (benefits everyone, independently).
“Insofar as an enhancement would provide only a positional advantage, I think there is no moral case for promoting it… but if there is at least some component that is intrinsic, then there is at least a prima facie case.” [09:33]
2. Rhetoric & Social Construction of ‘Enhancement’
[10:13]
Ann Kerr: Argues the line between enhancement and therapy is “problematic”—the definition of ‘normal’ shifts over time and context.
- Notes how the push for enhancement often emerges from technological and policy communities with vested interests.
- Warns of the expansion creep, e.g., ADHD diagnosis widening and Ritalin’s transition from therapy to cognitive enhancer.
“We’ve always got to be aware of what the normal is when we’re talking about enhancement, and to be aware that that shifts.” [12:00]
- Raises concerns about societal inequalities being widened under capitalism, as access to enhancement is mediated by financial means.
3. Technological Inequality, Distribution, and Social Engineering
[15:44]
Bostrom: Pushes back by comparing enhancements to other technologies (like laptops) that initially benefit elites but eventually disseminate.
- Asks whether similar logic would necessitate restricting access to all new technologies, not just biomedical ones.
Kerr:
- Emphasizes a fundamental difference between bodily interventions and technology-use, raising concerns about coercion and the ethics of “positive eugenics.”
- Points to historical abuses in the name of improving populations and the potential for enhancement mandates to infringe on autonomy.
4. Enhancement, Policy, and Market Considerations
[19:01]
Bostrom: Stresses the policy/market split isn't foundational—societies can, in theory, subsidize effective, inexpensive cognitive enhancers (like Modafinil: “costs less than a cafe latte a day” [20:22]), much as they do education.
Kerr:
- Probes potential unintended social sorting (example: cognitive enhancers in schools might primarily benefit already-privileged children).
- Warns enhancement often raises the bar for "success," thus maintaining inequalities:
“Probably what would happen would be that what it would mean to get a good grade would increase so that the bar would raise...These kind of technologies would probably have the same kind of effect.” [26:21]
5. Intrinsic Value of Effort vs. Shortcut Enhancements
[28:23]
Moderator: Raises unease with "shortcut" enhancements—i.e., drugs versus effort—suggesting intrinsic value in the process of self-improvement.
Bostrom: Counters that enhancement does not necessarily remove the need for effort; rather, it changes the standard of performance.
“You could still push yourself with the pill. It just means that the standard of performance increases.” [29:30]
Kerr:
- Argues enhancement feeds a culture of perpetual consumption and escalates social obligations (“more and more things we need to buy and consume to make us better…gets a bit wearisome, really.” [31:03])
6. Long-Term Perspectives: Existential Risks & Human Futures
[33:03]
Bostrom: Advocates a broad, future-oriented view focused on humanity’s long-term prospects, including existential risks. Argues that cognitive enhancement could help us navigate unprecedented challenges (e.g., superintelligent AI).
“My view…is that humanity in the current human condition is very much an abnormality from almost any conceivable perspective…” [33:12]
Kerr:
- Skeptical of “grand, large-scale policy” solutions, suggesting they're neither democratic nor practical, often reflecting elite priorities.
7. Enhancement: Who Decides What’s “Better”?
[53:22]
Audience Question: Raises the issue of value judgements in definitions of enhancement (“We don't know what the perfect human would be”).
Bostrom: Emphasizes focus on general-purpose “functionings”—like health and cognition—beneficial across various conceptions of the good life.
“Neurological development is useful for a wide range of different human ideals… I would favour that for the same reason [as removing neurotoxins from drinking water].” [55:24]
Kerr:
- Cautions that even within disability communities, not everyone seeks "enhancement;" sometimes access to basics (e.g., antibiotics for cystic fibrosis) is more important than ambitious genetic interventions.
“…people are quite content to live in bodies that are slightly falling apart...that's part of the human condition.” [57:33]
8. Enhancement & Social Pressures: When Choice Becomes Obligation
[32:22][70:16]
Kerr: Warns enhancement options can morph into social obligations (e.g., reproductive technologies and prenatal screenings that shift from choices to expected norms):
“That choice comes with obligations...choices are never just a matter of pure individual choice. They always come with social obligations.” [32:22]
9. Ethical Limits, Naturalness, and Caution
[76:11][78:41]
Audience & Bostrom: Discuss whether there is a "deep" ethical or philosophical basis for rejecting enhancement, referencing bioconservative arguments about unnaturalness and the “openness to the unbidden” (Michael Sandel).
Bostrom: More compelling are specific, contextual ethical worries—especially concerning emotional/personality-altering enhancements.
“I think cognitive enhancements are usually at the middle of the line. But once we get to personality, I think it's a lot more complex even to say what is a good personality... So maybe delaying some of those interventions until we have grown up more...might be a good idea.” [79:54]
Notable Quotes & Memorable Moments
-
On the Moral Value of Enhancement:
“If the advantages are purely positional, then there is no moral reason for doing it.”
— Nick Bostrom [09:33] -
On Societal Distribution of Technology:
“A biomedical response is something that's done to the body, in the body, of the body, as opposed to purchasing a laptop.”
— Ann Kerr [16:28] -
On Consumer Capitalism and Enhancement:
“It's actually about more and more things we need to buy and purchase and consume to make us better. And it just gets a bit wearisome, really...”
— Ann Kerr [31:03] -
On Effort vs Shortcut:
“You could still push yourself with the pill. Presumably it's still going to make a difference how hard you work.”
— Nick Bostrom [29:30] -
On Future Risks and Enhancement:
“What can we do to improve our chances of a long and prosperous future for humanity?”
— Nick Bostrom [33:12] -
Audience Challenge on Wisdom vs Intelligence:
“To equate cognitive ability with wisdom… is I think a mistake.”
— Audience Member [49:04]
Key Timestamps & Segments
- [00:20] — Defining enhancement vs. therapy
- [04:29] — Nick Bostrom’s opening remarks: Evaluation frameworks for enhancement
- [10:13] — Ann Kerr: Historical, social contexts and creeping definitions
- [15:44] — Debate: Is enhancement like other technology?
- [20:22] — Cost/benefit analysis: Pills vs. education
- [26:21] — Enhancement raising social “bars” and competitive pressures
- [29:44] — The ethics of doping: Fairness, positional goods, and sport
- [33:03] — Long-term/“future of humanity” perspective
- [53:22] — Who gets to define what counts as "enhancement"?
- [70:16] — Eugenics and prenatal interventions
- [76:11] — Naturalness arguments against enhancement
Conclusion
Ann Kerr and Nick Bostrom bring complementary perspectives—the one deeply wary of social inequality, medicalization, and creeping obligations, the other cautiously optimistic about the long-term benefits of (the right kind of) enhancement. Both agree on the need for case-by-case ethical scrutiny, a healthy skepticism toward market-driven narratives, and humility regarding the long-term impact of “improving humanity.” The audience’s thoughtful questions highlight enduring ambiguities: Who defines “better”? When does enhancement exacerbate inequalities? And how do we ensure that the choices we make today do not foreclose possibilities for future generations?
Consensus emerges in caution, nuance, and a rejection of simple answers.